18:26 , Nov 7, 2018 |  BioCentury  |  Emerging Company Profile

ABL bispecifics

Korean biotech ABL Bio Inc. is developing bispecifics for cancer and Parkinson’s disease, and has evidence suggesting its lead candidate against VEGF and DLL4 is more potent than at least one of its Western competitors....
18:27 , Sep 21, 2018 |  BC Week In Review  |  Company News

Ahead of Ph Ib data, Celgene declines to exercise option to OncoMed bispecific

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Sept. 20 that partner Celgene Corp. (NASDAQ:CELG) will not exercise its option to license OncoMed's bispecific antibody navicixizumab (OMP-305B83) as a result of "strategic product portfolio considerations." The bispecific targeting...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A method for differentiating HSPCs into megakaryocytes by overexpressing or activating one of 15 genes could help generate platelet-producing megakaryocyte colonies for thrombocytopenia. The method involves two steps: generating megakaryocyte progenitor cells...
19:32 , Jul 13, 2018 |  BC Week In Review  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
23:03 , Jul 2, 2018 |  BC Extra  |  Company News

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five of its antibody programs, excluding South Korea. ABL will receive $4.3 million up front and be eligible for $550...
20:14 , Jun 15, 2018 |  BC Week In Review  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million on June 8 in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment....
22:43 , Jun 8, 2018 |  BC Extra  |  Financial News

ABL snags $65M in series C

ABL Bio Inc. (Seongnam, South Korea) raised $65 million in a series C round led by new investors DS Asset Management, Alpen Route Asset Management, Quad Asset Management and Hana Financial Investment. ABL has now...